Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry
Main finding · Disease duration to first b/tsDMARD, female vs male, most recent cohort (≥ 2017)Result — go to the resultHazard ratio 0.9 95% CI 0.81–0.99Authors' conclusion
Later prescribing in women despite higher activity rates merits reflection.
Study context
- Population
- Bio-naïve rheumatoid arthritis (RA) patients from the BIOBADASER III registry who began their first b/tsDMARD between 2000 and 202378.1% women
- Participants
- 3,384 patients
- Exposure
- Women vs men with bio-naïve RA starting first b/tsDMARD
- Outcome
- Time from RA diagnosis to initiation of first biologic disease-modifying antirheumatic drug (bDMARD) or tsDMARD, by gender
Methodological detailsmultivariate Cox regression, Kaplan-Meier curves, linear regression models for DAS28, stratified by treatment start year
- Multivariate Cox regression
- Kaplan-Meier curves
- Linear regression models for DAS28
- Stratified by treatment start year
Main finding
As reported in the abstract
Disease duration to first b/tsDMARD, female vs male, most recent cohort (≥ 2017)
Hazard ratio
0.9
95% CI 0.81–0.99
P = 0.026
Womenvs Men
HR 0.9 (95% CI 0.81–0.99); P = 0.026
Observational data: associations, not effects.
Further findings
Age at treatment start
P < 0.001
Disease duration at treatment start
P = 0.031
Disease activity at treatment start
- Women: higher DAS28-ESR but not DAS28-CRP; higher subjective DAS28 components and ESR, lower CRP; no differences in objective components
Comorbidities
- Men higher CV risk; women more osteoporosis and Sjögren Syndrome
Original publication
Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry. Arthritis Res Ther. Published 14 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →